165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

J. O'Shaughnessy,S. Sousa,J. Cruz,L. Fallowfield,P. Auvinen,C. Pulido,A. Cvetanovic,S. Wilks,L. Ribeiro, M. Burotto, D. Klingbiel, D. Messeri,A. Alexandrou,P. Trask,J. Fredriksson, Z. Machackova, L. Stamatovic

Annals of Oncology(2020)

引用 17|浏览30
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要